Paper Details

  1. Home
  2. Paper Details

Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.

Author: IrlamJames H, MbuagbawLawrence, MursleenSara, RutherfordGeorge W, SiegfriedNandi, SpauldingAlicen B

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This systematic review examines the comparative effectiveness of efavirenz (EFV) and nevirapine (NVP), two common first-line non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV treatment. The study aims to determine which NNRTI is more effective for initial therapy.
Paper Details　
Original Abstract of the Article :
The advent of highly active antiretroviral therapy (ART) has reduced the morbidity and mortality due to HIV infection. The World Health Organization (WHO) ART guidelines focus on three classes of antiretroviral drugs, namely nucleoside or nucleotide reverse transcriptase inhibitors (NRTI), non-nucle...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450880/

データ提供：米国国立医学図書館（NLM）

Navigating the HIV Treatment Desert: Efavirenz or Nevirapine?

The HIV treatment landscape, like a vast desert, is constantly evolving. This systematic review investigates the comparative efficacy of two common non-nucleoside reverse transcriptase inhibitors (NNRTIs), efavirenz and nevirapine, in combination with two nucleoside or nucleotide-reverse transcriptase inhibitors (NRTIs) for initial HIV treatment. The researchers sought to determine which NNRTI offers the most effective treatment option for individuals newly diagnosed with HIV.

Seeking a Path Through the HIV Treatment Desert

The researchers, like explorers navigating a vast and uncharted desert, aimed to identify the most effective treatment path for HIV-infected individuals. Their review, encompassing a comprehensive analysis of existing research, sought to clarify the relative efficacy of efavirenz and nevirapine, ultimately guiding clinicians in choosing the most appropriate treatment regimen.

Finding the Right Oasis in the HIV Treatment Desert

This systematic review provides valuable insights into the comparative efficacy of efavirenz and nevirapine for initial HIV treatment. By understanding the relative strengths and weaknesses of each NNRTI, clinicians can make informed decisions about treatment choices, ensuring the best possible outcomes for their patients. The findings of this review will continue to guide HIV treatment strategies, helping to pave the way for more effective and personalized care.

Dr.Camel's Conclusion

This systematic review explores the comparative efficacy of two common NNRTIs in initial HIV treatment, helping to clarify the most effective treatment pathways for individuals newly diagnosed with HIV. This research provides valuable guidance for clinicians navigating the evolving landscape of HIV treatment.

Date :
  1. Date Completed 2017-02-06
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

27943261

DOI: Digital Object Identifier

PMC5450880

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.